CRNX vs. SMMT, BHVN, AXSM, INSM, RARE, PBH, ALKS, PRGO, HCM, and XENE
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Summit Therapeutics (SMMT), Biohaven (BHVN), Axsome Therapeutics (AXSM), Insmed (INSM), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), Alkermes (ALKS), Perrigo (PRGO), HUTCHMED (HCM), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Crinetics Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.
Crinetics Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Crinetics Pharmaceuticals had 19 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Crinetics Pharmaceuticals and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.45 beat Crinetics Pharmaceuticals' score of 0.17 indicating that Summit Therapeutics is being referred to more favorably in the news media.
Crinetics Pharmaceuticals currently has a consensus price target of $58.42, suggesting a potential upside of 21.70%. Summit Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 61.29%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Crinetics Pharmaceuticals.
Summit Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Crinetics Pharmaceuticals' return on equity of -52.68% beat Summit Therapeutics' return on equity.
Summit Therapeutics received 147 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.67% of users gave Crinetics Pharmaceuticals an outperform vote while only 57.00% of users gave Summit Therapeutics an outperform vote.
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 83.7% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Crinetics Pharmaceuticals beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
